A multicomponent topical formulation containing hydroxyapatite, fermented oils, baicalin and crocin demonstrated dual anti-aging mechanisms in human skin cells. The treatment reduced senescence-associated β-galactosidase activity and decreased inflammatory markers IL-6 and IL-8 in aged cells, while providing significant protection against high-energy visible blue-violet light at 445nm wavelength. Testing confirmed safety across 50 volunteers including those with sensitive skin. This represents a meaningful advance in topical anti-aging science by directly targeting senescent cells - the aged, dysfunctional cells that accumulate in skin and drive inflammation. Most skincare focuses on prevention through antioxidants or surface-level improvements, but senolytic approaches that actively remove or rehabilitate these problematic cells could fundamentally alter how we address skin aging. The blue light protection adds contemporary relevance given increased screen exposure. However, the study's limitation to cell culture models means real-world efficacy remains unproven. While promising, this formulation needs clinical trials measuring actual skin aging parameters over months to validate whether laboratory senolytic effects translate to visible improvements in human skin health and appearance.